Back to search

Article

CAR T-Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds against Hematological Malignancies

2018-11-21

Abstract excerpt

The advent of the genome editing era brings forth the promise of adoptive cell transfer using engineered chimeric antigen receptor (CAR) T-cells for targeted cancer therapy. CAR T-cell immunotherapy is probably one of the most encouraging developments for the treatment of hematological malignancies. In 2017, two CAR T-cell therapies were approved by the U. S Food and Drug Administration; one for the treatment of p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d3836e1b-d691-5aa1-8bb7-7dcad4967bce
DOI
10.20944/preprints201811.0525.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CAR T-Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds against Hematological MalignanciesDOI 10.20944/preprints201811.0525.v1
Select a neighboring publication to make it the new centre.